Medicine used for treating influenza, upper respiratory infection and viral pneumonia
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for viral pneumonia and upper respiratory tract, applied in the field of medicine, can solve the problems of improper treatment, long relief time, easy to cause bronchial, pneumonia, tuberculosis and other problems, and achieve the effect of reducing the amount of use
Pending Publication Date: 2016-05-04
SHANDONG ZHONGHAI PHARMA CO LTD
View PDF10 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0011] (1) After administration, the body temperature cannot be controlled within a short period of time, and the body temperature changes greatly;
[0012] (2) The antipyretic effect on influenza patients is not obvious, and the antipyretic time is long after administration;
[0013] (3) It takes a long
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0041] Embodiment 1 A kind of medicine for treating influenza, upper respiratory tract infection, viral pneumonia
[0042] The drug is marine algae glycoprotein;
[0043] Said marine algae glycoprotein, in parts by weight, includes sugar 1%, protein 99%,
[0044] The molecular weight is 0.2kDa;
[0045] The marine algae are: cyanobacteria;
[0046] The sugar is a polysaccharide;
[0047] The polysaccharides include: galactose, sialic acid, mannose, arabinose, rhamnose;
[0048] The protein includes: glutamic acid, lysine, hydroxyproline, threonine, arginine;
Embodiment 2
[0049] Embodiment 2 A kind of medicine for treating influenza, upper respiratory tract infection, viral pneumonia
[0050] The drug is marine algae glycoprotein;
[0051] Said marine algae glycoprotein, in parts by weight, comprises sugar 6%, protein 85%,
[0052] The molecular weight is 16kDa;
[0053] The marine algae is: green algae;
[0054] The sugar is a polysaccharide;
[0055] The polysaccharides include: galactose, sialic acid, mannose, arabinose, rhamnose;
[0056] The protein includes: glutamic acid, lysine, hydroxyproline, threonine, arginine;
Embodiment 3
[0057] Embodiment 3 A kind of medicine for treating influenza, upper respiratory tract infection, viral pneumonia
[0058] The drug is marine algae glycoprotein;
[0059]Said marine algae glycoprotein, in parts by weight, comprises sugar 15%, protein 74%,
[0060] The molecular weight is 3kDa;
[0061] The marine algae are: cyanobacteria;
[0062] The sugar is a polysaccharide;
[0063] The polysaccharides include: galactose, sialic acid, mannose, arabinose, rhamnose;
[0064] The protein includes: glutamic acid, lysine, hydroxyproline, threonine, arginine;
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
Thickness
aaaaa
aaaaa
Melting point
aaaaa
aaaaa
Fineness
aaaaa
aaaaa
Login to view more
Abstract
The invention provides a medicine used for treating influenza, upper respiratory infection and viral pneumonia. The medicine is glycoprotein or a mixture of polysaccharide and protein or polypeptide or protein. The glycoprotein provided by the invention has a stabilization effect on body temperatures of endotoxin pyrogenic domestic rabbits, and has an obvious antipyretic effect; the medicine provided by the invention is used for treating the influenza, the upper respiratory infection and the viral pneumonia, and no symptoms of bronchitis, pneumonia and tuberculosis; the complication is 0; the toxin-free concentration of the medicine to Vero-E6 cells is 100 mu g/ml, and has an obvious inhibition effect on SARS viruses. The medicine provided by the invention has obvious pharmacologic actions on seven aspects of in-vitro virus resistance, in-vivo virus resistance, bacterium inhibition, inflammation resistance, antipyretic action, pain alleviation and immunologic function improvement; the medicine has the characteristics of safety, high efficiency and no side effect and has functions of preventing and treating respiratory system diseases, and broad-spectrum anti-virus, anti-inflammatory, anticoagulation, bacteria resisting, antipyretic and immunity adjusting functions.
Description
technical field [0001] The invention relates to a medicine for treating influenza, upper respiratory tract infection and viral pneumonia, and belongs to the technical field of medicine. Background technique [0002] Influenza (abbreviated as influenza) is an acute respiratory infection caused by influenza virus, and it is also a highly contagious and fast-spreading disease. It is mainly spread through droplets in the air, person-to-person contact or contact with contaminated items. The typical clinical symptoms are: sudden onset of high fever, general pain, significant fatigue and mild respiratory symptoms. Generally, autumn and winter are the high incidence period, and the complications and death caused by it are very serious. [0003] Early clinical symptoms of influenza include fever, cough, sore throat, body pain, headache, fever, etc. Some patients may also experience diarrhea or vomiting, muscle pain or fatigue, red eyes, etc. Sudden high fever, body temperature over...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more